Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

NCT05223088 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

Immunotherapy
Gastrict Cancer

Interventions

DRUG: Tislelizumab
DRUG: Apatinib Mesylate
DRUG: oxaliplatin
DRUG: Tegafur

Sponsor

Fujian Cancer Hospital